Downgrades Buy Neutral X

CLSD Clearside Biomedical

Chardan Capital Markets

Downgrades Buy Neutral X

CLSD Clearside Biomedical

H.C. Wainwright

Downgrades Buy Hold X

CLSD Clearside Biomedical

Stifel

$2

Initiated Buy X

CLSD Clearside Biomedical

Chardan Capital Markets

$6

Initiated Outperform X

CLSD Clearside Biomedical

Oppenheimer

$5

Resumed Outperform X

CLSD Clearside Biomedical

Wedbush

$19 $9

Initiated Buy X

CLSD Clearside Biomedical

H.C. Wainwright

$10

Downgrades Buy Hold X

CLSD Clearside Biomedical

Needham

Downgrades Overweight Underweight X

CLSD Clearside Biomedical

JP Morgan

Reiterated Buy X

CLSD Clearside Biomedical

Needham

$18 $22

CLSD  Clearside Biomedical, Inc.

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.